Skip to main navigation

Overview
Shareholder Information
Events & Presentations
News
Corporate Governance
IR Contact
- Email Alerts
- Contact IR

News

News

News Category

Year

June 1, 2023

Oxurion to Participate in Upcoming Conferences

PDF Version

May 25, 2023

Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

PDF Version

May 22, 2023

Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC

PDF Version

May 15, 2023

Oxurion Announces Results of the Annual Shareholders’ Meeting of 2 May 2023

PDF Version

April 27, 2023

Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC

PDF Version

March 31, 2023

Oxurion Publishes 2022 Annual Report

EN

NL

March 20, 2023

Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL

PDF Version

March 14, 2023

Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes

EN

March 2, 2023

Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To €20 Million in Funding

EN

March 2, 2023

Funding Program between Oxurion and Negma Ends

EN

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12

Section Title

Who We Are
THR-149
News & Events
Let’s Talk

Connect with Us

LinkedIn
Twitter

Ⓒ2023 Oxurion NV. All rights reserved.